ALLMedicine™ Neuroblastoma Center
Research & Reviews 3,906 results
Proceedings of the National Academy of Sciences of the Un... Gkikas D, Stellas D et. al.
Sep 26th, 2021 - Nervous system malignancies are characterized by rapid progression and poor survival rates. These clinical observations underscore the need for novel therapeutic insights and pharmacological targets. To this end, here, we identify the orphan nucle...
https://doi.org/10.1038/s41388-021-02018-7 10.1136/bmj.j1863 10.1200/JCO.2008.16.6785 10.1186/s12943-017-0686-8 10.1038/ng.2529 10.1016/j.ccr.2012.02.010 10.1093/jnci/djh004 10.3892/ijo.2016.3792 10.18632/oncotarget.22011 10.1093/annonc/mds648 10.1080/2162402X.2018.1468953 10.1016/S1470-2045(13)70095-0 10.1002/ijc.24606 10.1158/1078-0432.CCR-20-4224 10.1016/j.tranon.2017.09.008 10.1038/ng.3438 10.1038/nature10910 10.1158/0008-5472.CAN-05-4618 10.1038/cddis.2013.84 10.1038/nbt.3001 10.1158/2159-8290.CD-16-0861 10.1038/s41467-021-21247-8 10.1055/s-2000-9677 10.1186/1471-2407-9-57 10.1101/cshperspect.a002287 10.18632/oncotarget.19662 10.1007/978-1-0716-0138-9_15 10.1093/jnci/djj330 10.1073/pnas.0506580102 10.1038/nature11003 10.1038/s41598-021-90701-w 10.3389/fonc.2019.01046 10.1016/j.lfs.2015.07.022 10.1016/j.cell.2014.04.039 10.1016/j.critrevonc.2007.03.001 10.1002/cncr.22879 10.1158/0008-5472.CAN-13-0248 10.1182/blood-2001-12-0169 10.3389/fcell.2019.00105 10.1038/ng.3333 10.1038/mt.2008.6 10.1038/leu.2014.130 10.1093/nar/gkaa216 10.1093/bioinformatics/19.2.185 10.1093/nar/gkv468 10.1200/JCO.2006.06.1879 10.1186/s13059-014-0523-y 10.1038/nature09609 10.1371/journal.pone.0021800 10.1101/gr.1239303 10.1093/bioinformatics/btr095
Oncogene Lebedev T, Vagapova E et. al.
Sep 25th, 2021 - Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-ris...
https://doi.org/10.1007/s00383-021-05014-w 10.1007/978-3-319-27443-0_96 10.1002/mpo.1139 10.1007/s00415-018-9138-7 10.1016/j.ejpn.2008.04.012 10.1002/ana.20539 10.1212/WNL.62.9.1526 10.1200/JCO.2011.37.9990 10.1007/s00428-002-0747-1 10.1016/j.pediatrneurol.2017.04.027 10.1016/S2352-4642(17)30130-X 10.1177/0883073811428816 10.1055/s-0037-1609038 10.1097/01.mph.0000212991.64435.f0 10.1002/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E 10.1177/1043454204272560
Pediatric Surgery International; Johnston WR, Hwang R et. al.
Sep 23rd, 2021 - Neuroblastoma is a childhood cancer of neural crest cells occasionally associated with opsoclonus-myoclonus-ataxia syndrome (OMAS), a paraneoplastic process characterized by ataxia, rapid eye movements, and muscle twitching. OMAS treatment and out...
Pediatric Blood & Cancer; Felix CA, Slater DJ et. al.
Sep 23rd, 2021 - Twelvepatients without therapy-related leukemia were studied after completing TOP2 poison chemotherapy in a high-risk neuroblastoma regimen. One patient harbored an inv(11) that was a KMT2A rearrangement. The KMT2A-MAML2 transcript was expressed a...
https://doi.org/10.1007/s40272-021-00469-9 10.1148/rg.2018170132 10.1016/S1470-2045(17)30186-9 10.1200/JCO.2014.59.4648 10.1080/14737140.2017.1285230 10.3390/children5090114 10.1056/NEJMoa0911123 10.1158/1078-0432.CCR-20-3909 10.1016/S1470-2045(18)30578-3 10.1200/JCO.2019.37.15_suppl.10013 10.1080/19420862.2017.1402997 10.1080/14737140.2017.1364995 10.1016/S1470-2045(17)30070-0 10.1200/JCO.2019.37.15_suppl.10014 10.3892/ijo.3.5.909 10.2147/BTT.S114530 10.4161/mabs.2.3.11782 10.3389/fonc.2020.601076 10.1016/j.jaapos.2014.11.005
Paediatric Drugs; Barone G, Barry A et. al.
Sep 21st, 2021 - Neuroblastoma is the most common extracranial solid tumour in children, accounting for 15% of all paediatric cancer deaths. High-risk neuroblastoma is a particularly challenging-to-treat form of disease that requires multimodality treatment, consi...
Guidelines 1 results
British Journal of Cancer; Beiske K, Burchill SA et. al.
Apr 30th, 2009 - Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task...
Drugs 46 results see all →
News 104 results
Jun 16th, 2021 - The results from three small studies of targeted therapy for rare brain tumors were "remarkable," according to Jaishri Blakeley, MD, a neurology professor at Johns Hopkins Medicine, Baltimore, who discussed the studies after they were presented at...
Dec 1st, 2020 - A novel chimeric antigen receptor (CAR) T-cell therapy developed by researchers at University College London (UCL) to target cancerous tumours has shown promising early results in children with neuroblastoma. In the UCL study, paediatric patients’...
Nov 26th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval for a new drug for certain patients with neuroblastoma based on response rate results in small open-label trials. The drug is naxitamab (Danyelza, Y-mAbs Therapeutics), a h...
Mar 27th, 2020 - Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system. It most frequently originates in ...
Jan 21st, 2020 - Adult survivors of pediatric cancers appear to be experiencing fewer major cardiac events in adulthood partly because of reduced radiotherapy exposure, especially among survivors of Hodgkin lymphoma, recent research published in BMJ has shown. “Co.